ATLANTA, GA -- October 17, 2006 -- PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, today announced at Neuroscience, Booth #1148, the introduction of its Geliance™ series, a new line of high-performance bio-imaging systems for fluorescence and chemiluminescence applications that further extends the Company’s portfolio of state-of-the-art imaging equipment for academic and pharmaceutical laboratories. These instruments offer top-of-the-line optical performance, with easy-to-use hardware and software to provide researchers a choice of optics and lighting options for DNA, RNA and protein chemiluminescent and fluorescent experiments. The Geliance series has many integrated features for increased productivity, including real-time image capture that enables images to be instantly ready to print or analyzed.

“Adding Geliance to our imaging offerings, combined with our reagents and applications expertise, provides scientists with a complete, end-to-end imaging solution, said Mary Duseau, business leader for Detection and Analysis Systems, PerkinElmer Life and Analytical Sciences. “It enables scientists to keep their focus on the pace and precision of their research with the peace of mind that they’re backed by PerkinElmer’s applications and service expertise.

“Geliance imaging systems were designed to help scientists manage increasingly heavy workloads and offer time-saving operation to help labs meet their ever-compressed deadlines,” Duseau added.

In addition to the new Geliance line, PerkinElmer also offers UltraVIEW™ Live Cell Imaging, and the market-leading, high-throughput CellLux™ fluorescent and LumiLux™ luminescent cellular imaging platforms.

The new Geliance series includes:

• The Geliance 200 Imaging System – an affordable, easy-to-use, advanced resolution system for 1-D documentation and analysis. It has a standard 1.4 megapixel camera, providing a wide range of capabilities for fluorescent stains.
• The Geliance 600 Imaging System – a high-performance 1.4 megapixel, 16-bit-cooled CCD camera system for fluorescence and chemiluminescence applications. Its innovative design allows for a choice of optics and lighting options, allowing clear images of even faint luminescence for a wide range of chemiluminescence-based applications including Western Lightning PLUS, ECL, SuperSignal and LumiGlo.

All Geliance systems are backed by PerkinElmer’s complete, integrated training and support. For more information on the Geliance Imaging Family visit www.perkinelmer.com/geliance.

Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Other Information
Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging. Photonics markets include sensors and specialty lighting.